pubrio
Parse Biosciences logo

Parse Biosciences

Privately Held
Research200+ employeesFounded 2018🇺🇸 United States
Headquarters
🇺🇸700 Dexter Ave N, Suite 600, Seattle, Washington 98109, US (+2)
Industry
Research
Employees
200+
Founded
2018
Company type
Privately Held
Ranking
#3,169,246

Parse Biosciences is a biotechnology company based in Seattle, founded in 2018. The company focuses on advancing single-cell genomics with innovative solutions that allow researchers to analyze complex biological systems efficiently. Their mission is to support breakthroughs in various fields, including developmental biology, immunotherapy, neurology, diabetes, vascular disease, and cancer. The company specializes in single-cell sequencing technologies, particularly through their Evercode™ Platform. This platform provides an end-to-end solution for library preparation, sequencing, and data analysis, enabling whole transcriptome sequencing and immune profiling without the need for custom instruments. Their offerings include Evercode™ Whole Transcriptome Kits and Immune Profiling Kits, which facilitate scalable workflows and detailed immune repertoire analysis. Parse Biosciences serves researchers and institutions in academic, clinical, and pharmaceutical settings, providing tools that enhance the study of cellular heterogeneity and disease mechanisms.

Specialties
ResearchBiotechnologyHealthcare
5 / 6
Active markets
United Kingdom · Germany · France
1
New markets
Russia
762
Signals
Last 90 days
-48%
Momentum
vs prior period
Expansion ScoreEarly
12 / 100

Global expansion

Live
United KingdomGermanyFrance
Up to 3 markets
Last 90 days
Stages
Exploring6Committing0Expanding0Scaling0
Recent activity
Advancing30d
New90d
+3more marketsLocked
3 of 6 shown

Unlock the market timeline & signal feed

Activity pulse

New Hiring activity — 2 fresh signals just appeared.

Last 90 days
Hiring
2New
Hiring
Marketing & PR
760-29%
Advertising
Product & Tech
0
No activity
+2more categoriesLocked
3 of 5 shown

Market entry timeline

The order this company entered each market — oldest to newest

1
🇬🇧United Kingdom1st market entered · 2024
Exploring
102 signals
2
🇩🇪Germany2nd market entered · 2024
Exploring
101 signals
3
🇫🇷France3rd market entered · 2024
Exploring
100 signals
+3more marketsLocked
3 of 6 shown
Current stageExploringTesting the waters
Confidence48%Medium
Tracking since2024first signal

Recent signals

Advertising🇬🇧 United Kingdomtoday

If you're doing single cell in 2026, you need to be in this room. Join us in London, January 27, for the Parse Biosciences user group meeting, featuring:🗣️ Customer talks on real-world applications📰 Latest Parse updates💬 Open discussion to swap approaches and best practices🤝 Networking with fellow single cell researchersRegister now: https://lnkd.in/dvr7CCMK ...

Advertising🇯🇵 Japanyesterday

[On-Demand Webinar] Why Single Cell RNA Sequencing?

Sign up to see the full signal feed

Good to know

Frequently Asked Questions Regarding Parse Biosciences

Quick answers about Parse Biosciences's business, markets, and growth signals.

Parse Biosciences is a biotechnology company based in Seattle, founded in 2018. The company focuses on advancing single-cell genomics with innovative solutions that allow researchers to analyze complex biological systems efficiently. Their mission is to support breakthroughs in various fields, including developmental biology, immunotherapy, neurology, diabetes, vascular disease, and cancer. The company specializes in single-cell sequencing technologies, particularly through their Evercode™ Platform. This platform provides an end-to-end solution for library preparation, sequencing, and data analysis, enabling whole transcriptome sequencing and immune profiling without the need for custom instruments. Their offerings include Evercode™ Whole Transcriptome Kits and Immune Profiling Kits, which facilitate scalable workflows and detailed immune repertoire analysis. Parse Biosciences serves researchers and institutions in academic, clinical, and pharmaceutical settings, providing tools that enhance the study of cellular heterogeneity and disease mechanisms.

800M+
Companies watched
50+
Local data sources
16
Movement signals
Daily
Refresh
“We reach accounts the week they land in-market — not the quarter after.”
Head of Growth · a 500+ revenue team on Pubrio

See the world’s companies move.

Book a walkthrough of the movement map with our team.

pubrio

Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.

Follow

Ask AI about Pubrio

© 2026 Pubrio. All rights reserved.